StockTipsArenaBeta

BUY Lupin Limited — Rajesh Palviya, Axis Securities

BUYLupin Limited

byRajesh Palviya, Axis SecuritiesHorizon: NA (inferred Swing (≤2wk))6 May 2026via CNBC Awaaz.

Entry₹2,442.9Inferred
Target₹2,520
Total upside +3.16% (call closed)
Stop lossNot given
At expiry₹2,285.419 May 2026, 3:30 pm
Expired-6.45%
Follow Rajesh Palviya for new calls(25% target hit, 162 closed calls)Get alertsWatch LUPIN for new buy/sell callsGet alertsSee 264 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 9 Sept, 9:41 pm IST
7 supporting1 neutral0 opposing
Supports the BUY call (7)

Lupin Limited has made its debut in the Dow Jones Best-in-Class Indices 2026, indicating strong performance and adherence to sustainability standards.

NSE · Press Release·19 May · today

(opens in new tab)

Lupin Ltd has received tentative approval from the U.S. FDA for its Revefenacin Inhalation Solution.

BSE · Company Update·18 May · today

(opens in new tab)

Lupin Limited inaugurated Atharv Ability, an advanced multidisciplinary neuro-rehabilitation center in Delhi.

NSE · Press Release·15 May · 4d ago

(opens in new tab)

Lupin Ltd has received approval from the U.S. FDA for its Famotidine Injection, USP.

BSE · Company Update·13 May · 5d ago

(opens in new tab)

3 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·13 May · 6d ago

Neutral / worth noting (1)

The Audited Financial Results for the quarter and year ended March 31, 2026 and recommendation of Final Dividend of Rs. 18 /- per equity share i.e. 900 % of the Face Value of Rs. 2/- each ....

BSE · Board Meeting·7 May · 2w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.